ChiCTR2300077451 版本V1.1 版本创建时间2024/05/28 14:30:33 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300077451 

最近更新日期:

Date of Last Refreshed on:

2023-11-09 09:41:37 

注册时间:

Date of Registration:

2023-11-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

右美托咪定联合纳布啡对腹腔镜减重手术术中血流动力学及全麻恢复期苏醒质量的影响

Public title:

The effect of dexmedetomidine combined with nabuprofen on hemodynamics and quality of general anesthesia recovery during laparoscopic weight loss surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右美托咪定联合纳布啡对腹腔镜减重手术术中血流动力学及全麻恢复期苏醒质量的影响

Scientific title:

The effect of dexmedetomidine combined with nabuprofen on hemodynamics and quality of general anesthesia recovery during laparoscopic weight loss surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈玉琴 

研究负责人:

陈玉琴 

Applicant:

Chen Yuqin 

Study leader:

Chen Yuqin 

申请注册联系人电话:

Applicant telephone:

+86 137 0064 4755

研究负责人电话:

Study leader's
telephone:

+86 137 0064 4755

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

13700644755@163.com

研究负责人电子邮件:

Study leader's E-mail:

13700644755@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

云南省昆明市人民东路245号

研究负责人通讯地址:

云南省昆明市人民东路245号

Applicant address:

14/5000 245 Renmin East Road, Kunming City, Yunnan Province

Study leader's address:

14/5000 245 Renmin East Road, Kunming City, Yunnan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

昆明市延安医院

Applicant's institution:

Kunming Yan'an Hospital

研究负责人所在单位:

昆明市延安医院

Affiliation of the Leader:

Kunming Yan'an Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-104-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

昆明市延安医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Yan'an Hospital in Kunming City

伦理委员会批准日期:

Date of approved by ethic committee:

2023-07-04 00:00:00

伦理委员会联系人:

李琳

Contact Name of the ethic committee:

Li Lin

伦理委员会联系地址:

昆明市延安医院

Contact Address of the ethic committee:

Kunming Yan'an Hospital

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 871 6321 1318

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

昆明市延安医院

Primary sponsor:

Kunming Yan'an Hospital

研究实施负责(组长)单位地址:

云南省昆明市昆明市延安医院麻醉科

Primary sponsor's address:

Anesthesiology Department of Yan'an Hospital, Kunming City, Yunnan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

云南省

市(区县):

昆明市

Country:

China

Province:

Yunnan Province

City:

单位(医院):

昆明市延安医院

具体地址:

云南省昆明市人民东路245号

Institution
hospital:

Kunming Yan'an Hospital

Address:

245 14/5000 245 Renmin East Road, Kunming City, Yunnan Province

经费或物资来源:

导师提供

Source(s) of funding:

raise independently

研究疾病:

肥胖  

Target disease:

Obesity

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究右美托咪定复合纳布啡能否为肥胖手术患者提供更稳定的血流动力学变化及更高的苏醒质量  

Objectives of Study:

To explore whether dexmedetomidine combined with nalbuphine can provide more stable hemodynamic changes and higher quality of recovery in bariatric surgery patients

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)BMI≥28kg/m2; (2)ASAI~III级; (3)年龄18-60岁。

Inclusion criteria

(1) BMI ≥ 28kg/m2; (2) ASAI~III level; (3) Age 18-60 years old.

排除标准:

(1)严重高血压或低血压者; (2)严重心肺、肝肾功能疾病; (3)有严重心律失常或窦性停搏史者;房室传导阻滞及窦性心动过缓患者(术前HR<50次/分) (4)对右美托咪定或纳布啡过敏者; (5)长期应用镇静镇痛药者; (6)预计面罩通气困难和重度阻塞性睡眠呼吸暂停综合征患者,需要清醒插管及术后拟送ICU者; (7)有精神病史无法配合者。

Exclusion criteria:

(1) Severe hypertension or hypotension; (2) Severe heart, lung, liver, and kidney functional diseases; (3) Individuals with a history of severe arrhythmia or sinus arrest; Patients with atrioventricular block and sinus bradycardia (preoperative HR<50 beats/minute) (4) Individuals who are allergic to dexmedetomidine or nabrphine; (5) Long term use of sedatives and analgesics; (6) Patients with difficulty in mask ventilation and severe obstructive sleep apnea syndrome are expected to require conscious intubation and planned to be sent to the ICU after surgery; (7) Individuals with a history of mental illness who are unable to cooperate.

研究实施时间:

Study execute time:

From 2023-11-10 00:00:00 To 2024-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-11-10 00:00:00 To 2024-02-29 00:00:00

干预措施:

Interventions:

组别:

S组

样本量:

20

Group:

Group S

Sample size:

干预措施:

舒芬太尼+咪达唑仑+丙泊酚+瑞芬太尼+维库溴铵

干预措施代码:

Intervention:

Sufentanil + midazolam + propofol + remifentanil + Vecuronium bromide

Intervention code:

组别:

D组

样本量:

20

Group:

Group D

Sample size:

干预措施:

右美托咪定+舒芬太尼+咪达唑仑+丙泊酚+瑞芬太尼+维库溴铵

干预措施代码:

Intervention:

Dexmedetomidine + Sufentanil + midazolam + propofol + remifentanil + Vecuronium bromide

Intervention code:

组别:

ND组

样本量:

20

Group:

Group ND

Sample size:

干预措施:

纳布啡+右美托咪定+舒芬太尼+咪达唑仑+丙泊酚+瑞芬太尼+维库溴铵

干预措施代码:

Intervention:

Nalbuphine + dexmedetomidine + Sufentanil + midazolam + propofol + remifentanil + Vecuronium bromide

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

云南 

市(区县):

 

Country:

Chian

Province:

Yunnan Province

City:

单位(医院):

昆明市延安医院 

单位级别:

三甲 

Institution
hospital:

Kunming Yan'an Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术中血流动力学

指标类型:

主要指标

Outcome:

Intraoperative hemodynamics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Ricker 镇静-躁动评分

指标类型:

主要指标

Outcome:

Sedation-agitaion scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良的Minogue量表

指标类型:

主要指标

Outcome:

Modified Minogue scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

拔管时间

指标类型:

次要指标

Outcome:

Extubation time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

NRS scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PONV评分

指标类型:

次要指标

Outcome:

PONV score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Athens失眠量表

指标类型:

次要指标

Outcome:

Athens insomnia scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究小组负责人由随机数字表法产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

The leader of the research team generates random sequence by random number table method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

对麻醉医生不设盲,对患者及其他研究人员设盲。

Blinding:

Do not blind anesthesiologists, but blind patients and other researchers.

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not share

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-11-09 09:40:11